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Activator proteins regulate eukaryotic RNA polymerase II (Pol II) transcription in response to developmental and environmental signals. They bind to the DNA recognition sites of target genes with a sequence-specific DNA-binding domain, and recruit components of the Pol II machinery through a transcriptional activation domain (TAD) 1, 2 . Activators have been classified as acidic, glutamine-rich, proline-rich and serine/threonine-rich, depending on the preponderance of amino acids in their TAD 3 . An archetypal acidic activator is the herpes simplex virus protein 16 (VP16), which activates the expression of immediate early viral genes during infection [4] [5] [6] [7] [8] . VP16 exerts its activating function through a C-terminal TAD that includes residues 413-490 (refs. 9-13) .
The VP16 TAD has been intensely used for studying transcriptional activation. Usually, the VP16 TAD is fused with its N terminus to the DNA-binding domain of the yeast transcription factor Gal4. The resulting Gal4-VP16 activator fusion protein stimulates transcription from promoters that contain Gal4-binding sites in the yeast and mammalian transcription systems in vivo 14, 15 and in vitro 16, 17 . This indicates that basic mechanisms of transcription activation are conserved amongst eukaryotes. The VP16 TAD targets basal Pol II transcription factors, including TFIIA, TFIIB, TFIID, the TFIIH subunit Tfb1/p62 (yeast/human) and the Mediator co-activator [18] [19] [20] [21] [22] [23] . The VP16 TAD binds the Mediator subunit Med25 (also called Arc92) [24] [25] [26] [27] , which is specific to higher eukaryotes. Med25 consists of two domains, the activator interaction domain (ACID) 24 that binds the VP16 TAD, and a 'von Willebrand factor type A' domain that anchors Med25 to Mediator 24 . Mediator generally conveys regulatory information by forming a bridge between activators and the basal Pol II machinery 28, 29 . Whereas information on the core Mediator structure is emerging, structural information about its more peripheral activator-binding domains is limited to the KIX domain in subunit Med15 (or Arc105) 30, 31 .
The VP16 TAD is intrinsically flexible, whereas the VP16 core domain (residues 49-402) forms a stable structure 23, [32] [33] [34] . The TAD contains two functional subdomains, H1 (residues 410-452) and H2 (residues 453-490), which activate transcription independently 35, 36 . Both H1 and H2 contain acidic amino acids, but specific bulky hydrophobic and aromatic residues are required for their function [36] [37] [38] [39] . H2 has been proposed to adopt an α-helical conformation when bound to TFIIB 40 . NMR analysis revealed a nine-residue amphipathic α-helix in H2 that docks onto a PH fold in Tfb1 21 . On the basis of these and other results it is assumed that acidic TADs are flexible in their free state, but become transiently structured upon interaction with their target proteins.
Here we report the NMR structure of the Mediator Med25 ACID and analyze its structural and functional interaction with the VP16 TAD. The structure revealed a fold that has not previously been described in activator target domains. NMR chemical shift perturbation analysis combined with biochemical assays showed that VP16 TAD interacts with an extended surface of Med25, in contrast to its known interaction with Tfb1. These results show that a canonical acidic TAD can adapt to unrelated target surfaces, and shows that diverse protein folds have evolved for TAD binding.
RESULTS

Med25 ACID solution structure
We prepared recombinant human Med25 ACID (residues 394-543; Fig. 1a and Supplementary Fig. 1 ) and determined its solution structure using multidimensional NMR spectroscopy (Online Methods and Table 1 ). The secondary structure is defined by 13 C secondary chemical shifts and supported by H-D exchange experiments (Supplementary Fig. 2 ). The ensemble of ten lowest-energy conformers is shown in Figure 1b . ACID comprises a seven-stranded β-barrel framed by three α-helices (Fig. 1c) . The β-barrel consists of antiparallel strands (β1, Leu400-Trp408; β2, Arg425-Asn434; β3, Gln446-Pro454; β4, Ser468-Phe475; β5, Phe494-His499; β6, Val510-Ser516; β7, Ile521-Ile526), with the exception of a short parallel arrangement between residues Val405 and Trp408 in β1 and residues Lys447 and Met450 in β3. Helix α1 (Gln455-Arg466), between β3 and β4, is slightly kinked at residues Gly462 and Pro463, resulting in a 3 10 -helix at residues Gly462-Arg466. Helix α2 (Leu480-Met490) connects strands β4 and β5, and helix α3 (Gln530-Asn543) forms the C-terminal region. Helix α3 is well defined by short-range NOEs. It is poised away from the central protein core, but nevertheless its orientation is well defined on the basis of eight NOEs to residues in the core domain. Loops β1-β2 (Lys411-Leu423), β2-β3 (His435-Lys440) and β5-β6 (Phe500-Arg509) contain highly mobile regions, consistent with the paucity of NOEs, 13 C secondary chemical shifts and low { 1 H}-15 N heteronuclear NOE values (Supplementary Fig. 2) .
A novel activator target fold
We carried out a structural similarity search with DALI 41 but found no known activator target domains. However, the overall fold of Med25 ACID resembled the Spen paralog and ortholog C-terminal (SPOC) domain in the human transcriptional co-repressor SHARP 42 ( Fig. 1c) and the β-barrel fold in the Ku70 and Ku80 subunits of the heterodimeric DNA repair factor Ku70-Ku80 (ref. 43) . The SPOC domain shares the central β-barrel and two flanking helices with Med25 ACID, but differs from the ACID structure by the presence of four additional helices (green in Fig. 1c) . Helices αC and αD of the SPOC domain correspond topologically to helices α1 and α2, respectively, of ACID (Fig. 1c) , whereas the SPOC domain also contains two N-terminal and two C-terminal helices. The N-terminal helices αA and αB enclose the first two strands in the barrel, whereas the C-terminal helices αE and αF are inserted into a loop between β6 and β7. Compared to that of ACID, the central β-barrel of the SPOC domain shows a discontinuity in strand β3 and a disruption of the characteristic pattern of hydrogen bonds between β3′ and the adjacent strand β5. Therefore, ACID differs from the SPOC domain by the absence of four helices that flank the barrel in the SPOC domain and by the presence of a C-terminal helix α3 with a unique location and a long loop connecting β1 and β2.
The VP16 TAD binds a large surface of Med25 ACID To study the binding of ACID to the VP16 TAD, we expressed the VP16 TAD as an N-terminal fusion protein with the Gal4 DNA-binding domain (see Supplementary Methods). Using a TEV protease cleavage site between the Gal4 domain and TAD, we prepared milligram quantities of a stable variant of VP16 TAD with a hexahistidine tag at its C terminus. To identify the surface of ACID that interacts with the VP16 TAD, we performed NMR chemical shift perturbation experiments. We recorded 2D 1 H, 15 N HSQC spectra of 15 Intra-residue 297
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A r t i c l e s A r t i c l e s changes occurred upon TAD binding (Fig. 2a) . The binding was in the fast to intermediate exchange regime on the NMR chemical shift time scale (Fig. 2) . Saturation was achieved at about equimolar concentration of TAD and ACID, indicating a high-affinity interaction in the low micromolar to high nanomolar range. Numerous residues showed substantial chemical shift changes upon addition of VP16 TAD ( Fig. 2 and Supplementary Fig. 1 ). Additional residues experienced substantial line-broadening, which suggests that there was conformational exchange in the binding interface (Figs. 2b-d, 3 and Supplementary  Fig. 1 ). Mapping the affected residues onto the ACID structure revealed that VP16 TAD shared an extended binding interface with ACID (Fig. 2d) . These data suggest that the VP16 TAD engages in numerous contacts over a large surface area of ACID that comprises the central β-barrel and helices α1 and α3 at multiple sites.
TAD subdomains H1 and H2 bind opposite ACID faces
To investigate whether the two TAD subdomains contacted distinct patches on the extended ACID activator-binding surface, we carried out NMR titration experiments with the isolated H2 subdomain (Fig. 2e) . Saturation was achieved only at eight-fold molar excess of H2 over ACID, indicating that the interaction with H2 was weaker than the interaction with the complete TAD. The NMR signals of many residues showed substantial line-broadening at two-fold molar excess of the VP16 TAD, presumably linked to conformational dynamics, and thus could not be further analyzed. However, there are already substantial chemical shift perturbations at a 1.5-fold molar excess of H2 over ACID, affecting a number of residues on one face of the ACID structure ( Fig. 2e-g ). Residues on the opposite face, such as Leu406 and Glu407, which were affected in the titration experiments with the complete TAD, did not show chemical shift changes upon addition of H2 even at saturating concentrations. More generally, residues that were perturbed by H2 binding formed a subset of the residues that were (Fig. 2b-d) . Spheres indicate residues with signals that show binding in intermediate exchange (Fig. 2c and Supplementary Fig. 1 ). Dashed circles indicate opposite ACID faces interacting mainly with H1 and H2, respectively.
A r t i c l e s perturbed upon binding of the entire TAD. Whereas H1 binds to one ACID face, H2 binds to the opposite face of the domain (Fig. 3) . Both subdomain-binding faces contain conserved exposed residues (Val405, Leu423 and Lys447 on the H1 face; Leu514, Arg466 and Met470 on the H2 face) that might interact with residues of VP16 required for its function 37, 39 . These results indicate that the TAD subdomains H1 and H2 do not compete for the same ACID surface but rather bind to distinct H1-and H2-binding patches on opposite faces of ACID.
VP16-ACID interaction relies on a conserved basic residue
To further investigate the TAD-ACID interaction biochemically, we used an electrophoretic mobility shift assay (EMSA; Online Methods). This assay used a fluorescently labeled DNA encompassing a Gal4-binding site and allowed us to monitor the formation of a binary complex of the Gal4-VP16 fusion protein with DNA, and also the formation of a ternary complex of the Gal4-VP16-DNA complex with ACID (Fig. 4a) . Formation of the ternary complex was seen as a supershift in the EMSA assay, and directly indicated an interaction between VP16 and ACID. To probe structural determinants in the interface, we mutated sites on ACID that showed strong perturbations in the NMR titration experiments. We generated 16 point mutant variants of ACID (Q455A, Q456A, L458A, T459A, T459V, R466E, R466A, S468A, V471A, V471L, L514A, S516A, K518A, K519A, L525V and L525A) and tested their interaction with VP16. All variants of ACID bound VP16 in the EMSA supershift assay (data not shown), except the charge-reversal variant R466E, which abolished the supershift (Fig. 4a) . These results confirm that binding of VP16 to ACID is robust and might rely on multiple redundant contacts, and they show that residue Arg466 of ACID forms a crucial interaction 'hot spot' . This basic residue lies within the H2-binding face (Fig. 3) and is conserved among ACID homologs (Supplementary Fig. 1 ).
Functional VP16 interaction with TAD-binding ACID surface
To investigate whether the characterized interaction between VP16 and ACID is functionally important during activated transcription, we established a quenching assay. We performed in vitro activated transcription assays with yeast nuclear extracts on the HIS4 promoter with an upstream Gal4-binding site 44 . The Gal4-VP16 fusion protein is a potent transcriptional activator in this system (Fig. 4b, lane 1) . The addition of recombinant ACID quenches the transcription signal, apparently by competing with VP16 targets in the yeast extract (Fig. 4b, lanes  2-4) . Thus this assay monitors whether human ACID interferes with functional interactions between VP16 and the basal Pol II machinery during activated transcription in vitro. We tested five of the above recombinant ACID point mutant variants in the quenching assay. The variants quenched the transcription signal to different extents, but generally less than wild-type ACID, supporting the idea that the residues identified in NMR titration are involved in VP16 binding ( Supplementary Fig. 3a,  lanes 1-13) . The ACID variant R466E had the strongest effect and only quenched transcription to a low extent (Fig. 4b, lanes 5-7) , consistent with its key role in VP16 binding as observed in the EMSA assay.
H1 and H2 cooperate during transcription activation in yeast
To evaluate the contributions of the VP16 subdomains to the activation of transcription in yeast, we prepared fusion proteins of the Gal4 DNAbinding domain with wild-type H1 or H2, with H1 or H2 mutated at functionally required hydrophobic residues, and with TAD mutated at A r t i c l e s functionally required hydrophobic residues in H1 or H2 (TAD H1mt and TAD H2mt, respectively; Fig. 2a ). In these assays H2, but not H1, could activate transcription alone, albeit weakly (Fig. 4c, lanes 6, 7, 15, 16 ). Consistently, TAD that carried a mutation in H2 supported activated transcription only weakly (Fig. 4c, lanes  13, 14) , whereas TAD that carried a mutation in H1 strongly activated transcription, to nearly the levels of wild-type TAD (Fig. 4c, lanes 4, 5) . Thus, the VP16 TAD subdomains H1 and H2 cooperate during activated transcription in the yeast system, with the main contribution coming from H2.
The ACID-VP16 interaction is functional in the human system Finally, we investigated whether the characterized VP16-ACID interaction is relevant in transcription activation in the human system. We investigated the quenching of activated transcription in human B-cell nuclear extracts by wild-type ACID and five ACID point mutant variants (Fig. 4d, lanes 1-13) . Consistent with our observations in the yeast transcription system, the addition of wild-type ACID quenched transcriptional activation (Fig. 4d, lanes 2, 3) whereas addition of the R466E variant showed hardly any effect (Fig. 4d, lanes 4, 5) . Furthermore, we studied the capability of ACID to interfere with another activator, SP1. ACID, but not the ACID variant R466E, quenched transcription activation by SP1 (Supplementary Fig. 3b , lanes 6-10), indicating that ACID uses the same binding surface for diverse activators. Thus, the VP16-ACID interface characterized here by NMR is functionally relevant in the yeast and human transcription systems.
DISCUSSION
An important goal in the field of transcription regulation is to understand how activators function through the central coactivator complex Mediator (Fig. 5) . Mediator integrates signals from activators bound upstream of the core promoter where Pol II and the basal factors assemble into the initiation complex. Structural information on activator-binding Mediator subunits and their activator interactions at a molecular level are an essential step toward this goal. We have described the solution structure of the VP16 activator interaction domain in the human Mediator, the ACID domain in Mediator subunit Med25. We showed by NMR titration that VP16 binds to an extended surface of ACID and assigned two opposite faces to the interaction with the VP16 TAD subdomains H1 and H2. Consistently, H1 and H2 bind to ACID in a noncompetitive manner and cooperate during promoter-dependent activated transcription in yeast. The TAD-binding ACID surface is conserved among higher eukaryotes and is functionally relevant because it is required for efficient quenching of transcription in vitro.
Until now, structural information on activator-binding domains in Mediator was limited to the KIX domain in subunit Med15 (Arc105) 30, 31 . This domain shows an entirely α-helical fold, in strong contrast to ACID, which contains a central β-barrel fold (Fig. 6) . More generally, the fold of Med25 ACID is unique amongst known activator target domains 21, [45] [46] [47] such as Tfb1, Mdm2, PAS-B and the CBP KIX domain, which are all unrelated in structure (Fig. 6) . However, there are two domains with a fold that resembles that of Med25 ACID in another human protein, PTOV1, which is overexpressed in prostate cancers 48 and is involved in cell proliferation 49 ( Supplementary Fig. 4) . As the amino acid residues of Med25 ACID that are involved in TAD binding are generally conserved in PTOV1, the two domains probably serve as activator-binding modules (Supplementary Fig. 4) .
In contrast to the variety of target domain folds, activators form similar helical segments in all available structures of activator-target complexes 21, [45] [46] [47] ( Fig. 6) . Unfortunately, we could not resolve an NMR structure of the VP16 TAD-ACID complex owing to substantial line-broadening of NMR signals in the binding interface (Supplementary Fig. 5 ). Nevertheless, analysis of 13 C secondary chemical shifts for the bound H2 peptide suggested that a central region comprising residues Ala471-Ala482 adopts a helical conformation (Supplementary Fig. 6 ). The line-broadening observed in both ACID and VP16 TAD suggests that the complex and the binding interface show conformational dynamics. As the ACID-TAD interaction is nevertheless tight and specific, this suggests that the activator might adopt multiple conformations on the same target surface. Such conformational flexibility is consistent with the general observation that activators form structured segments only transiently upon interaction with their targets through induced folding of helical segments 23, 50 .
Conformation flexibility in TADs also explains the promiscuity of activators with respect to different target surfaces. In particular, VP16 binds different target proteins in the yeast and human systems. VP16 is a very strong activator in yeast even though yeast Mediator contains neither Med25 nor another subunit with ACID homology. Although the specific VP16 targets differ, VP16 TAD uses its two subdomains H1 and H2 in a synergistic manner in both systems, indicating that the yeast transcription machinery contains at least two nonoverlapping sites that can bind to the two TAD subdomains.
Our results provide insights into the evolution of Mediator and Mediatordependent transcription regulation. Whereas the yeast Mediator contains 25 subunits that are mostly conserved throughout the eukaryotes 25 , Mediator in higher eukaryotes contains additional, specific subunits and forms several distinct multiprotein subcomplexes 51, 52 . The conserved Mediator core apparently contains a limited number of activator-binding target domains, whereas additional target domains are present on the extended surfaces of Mediator complexes from higher eukaryotes. The increase in target domain number and types might have made possible more complex transcriptional regulation. This might include processes that are specific to higher eukaryotes, such as differentiation or immune responses, and increased cooperativity might have allowed sharper on-off transitions. Surface extension of Mediator complexes during evolution was probably facilitated by the ability of activators to adapt to different targets.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession code. Coordinates of ten ACID structures have been deposited with the protein data bank under accession code 2XNF. A r t i c l e s 
